Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Dyslipidaemia in 2015

Advances in treatment of dyslipidaemia

Nature Reviews Cardiology volume 13, pages 74–75 (2016)Cite this article

Subjects

Statins remain the first-line therapy for dyslipidaemia. In 2015, however, effectiveness in reducing serum cholesterol levels and decreasing rates of cardiovascular disease in combination with statins has been demonstrated for two new classes of drugs: cholesterol-absorption inhibitors and PCSK9 inhibitors. The latter rival statins in their capacity to lower cholesterol levels.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown).

References

  1. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385, 1397–1405 (2015).

  2. Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387–2397 (2015).

    Article  CAS  Google Scholar 

  3. Jarcho, J. A. & Keaney, J. F. Jr. Proof that lower is better — LDL cholesterol and IMPROVE-IT. N. Engl. J. Med. 372, 2448–2450 (2015).

    Article  CAS  PubMed  Google Scholar 

  4. Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489–1499 (2015).

    Article  CAS  Google Scholar 

  5. Sabatine, M. S. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500–1509 (2015).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

S.M.G. is employed and supported by the Veterans Affairs Medical Center, Dallas, Texas, USA.

Author information

Authors and Affiliations

  1. Scott M. Grundy is at the Center for Human Nutrition and Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Suite Y3.206, Dallas, Texas 75390-9052, USA.,

    Scott M. Grundy

Authors
  1. Scott M. Grundy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott M. Grundy.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grundy, S. Advances in treatment of dyslipidaemia. Nat Rev Cardiol 13, 74–75 (2016). https://doi.org/10.1038/nrcardio.2015.208

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2015.208

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing